Photo from wikipedia
l‐DOPA‐induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5‐HT1A partial agonist) have shown promising results in the treatment of PD and LID,… Click to show full abstract
l‐DOPA‐induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5‐HT1A partial agonist) have shown promising results in the treatment of PD and LID, however no 5‐HT‐based treatment has been approved in PD. The present study was aimed to investigate how the substantia nigra pars reticulata (SNr) is affected by buspirone and whether it is a good target to study 5‐HT antidyskinetic treatments.
Keywords:
nigra pars;
pars reticulata;
treatment;
substantia nigra;
buspirone
Journal Title: British Journal of Pharmacology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Pharmacology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!